The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?-Reference-Cited by-同舟云学术

The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?

Published:2021-11-02 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Peters Ruth¹²^ORCID,Dodge Hiroko H.³,James Sarah⁴,Jicha Gregory A.⁵,Meyer Pierre‐Francois⁶,Richards Marcus⁴,Smith A. David⁷,Yassine Hussein N.⁸,Abner Erin⁵,Hainsworth Atticus H.⁹¹⁰^ORCID,Kehoe Patrick G.¹¹,Beckett Nigel¹²,Anderson Craig S.¹³,Anstey Kaarin J.¹²

Affiliation:

1. Neuroscience Research Randwick New South Wales Australia

2. Department of Psychology University of New South Wales Sydney New South Wales Australia

3. Department of Neurology Oregon Health & Science University Portland Oregon USA

4. MRC Unit for Lifelong Health and Ageing at UCL University College London London UK

5. University of Kentucky Lexington Kentucky USA

6. Center for Studies on the Prevention of Alzheimer's Disease (PREVENT‐AD) Verdun Québec Canada

7. OPTIMA Department of Pharmacology University of Oxford Oxford UK

8. Departments of Medicine and Neurology University of Southern California Los Angeles California USA

9. Molecular and Clinical Sciences Research Institute St Georges University of London London UK

10. Department of Neurology St George's Hospital London UK

11. Bristol Medical School University of Bristol Bristol UK

12. Guys and St Thomas’ NHS Foundation Trust London UK

13. The George Institute for Global Health Faculty of Medicine University of New South Wales Sydney Australia

Funder

National Institutes of Health

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12393

Reference33 articles.

1. PrinceM WA GuerchetM AliG‐C WuY‐T PrinaM World Alzheimer Report 2015 The Global impact of dementia in World Alzheimer Report.2015. Alzheimer's Disease International.https://www.alzint.org/resource/world‐alzheimer‐report‐2015/

2. Policy Brief 2018 Renewing priority for dementia: where do we stand?

3. John Snow, MD: Anaesthetist to the Queen of England and Pioneer Epidemiologist

4. A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence

5. Dementia prevention, intervention, and care

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can the gut microbiome inform the effects of omega-3 fatty acid supplementation trials on cognition?;Current Opinion in Clinical Nutrition & Metabolic Care;2023-12-26

2. Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective;Cell Reports Medicine;2023-06

3. Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non–Muscle-Invasive Bladder Cancer;JAMA Network Open;2023-05-19

4. “Exceptions that prove the rule”–Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia‐Alzheimer's disease syndrome?;Alzheimer's & Dementia;2022-03

5. Blood pressure change and cognition in childhood and early adulthood: a systematic review;Therapeutic Advances in Chronic Disease;2022-01